Cramer: Promising data from coronavirus drug trial ‘beginning of the end of the true nightmare’

Investing News

Jim Cramer

Scott Mlyn | CNBC

CNBC’s Jim Cramer said Wednesday that positive news from Gilead Sciences about a potential treatment for the coronavirus marked a turning point in the fight against Covid-19.

“What I regard this as is the beginning of the end of the true nightmare, which is that it’s a death sentence,” Cramer said on “Squawk Box.”

U.S. stocks soared on Wednesday after Gilead indicated it was seeing positive, preliminary signs about the effectiveness of its antiviral remdesivir in treating coronavirus patients.

Cramer has been hopeful about remdesivir as a possible treatment.

Last week, the “Mad Money” host said, he believes that scientists testing treatments for the coronavirus will succeed in getting patients “out of the hospital faster” and reducing “death sentence” concerns.

On Thursday, Cramer said at the time, “I do feel better about what Gilead is doing.”

Articles You May Like

Two New Reasons to Stay Bullish on AI Stocks
Trump says his administration will check Fort Knox ‘to make sure the gold is there’
Strong Earnings Should Keep Stocks on a Winning Path
Humanoid Robots: Betting on the Next Big AI Breakthrough
Top Wall Street analysts are optimistic about the potential of these 3 stocks